




## Is the Open Surgery First or Endovascular First Approach Controversy Still Alive for CLTI

### What Percentage Of An Interventionalist's Patients Should be Treated By Open Surgery?

Marianne Brodmann  
Division of Vascular Medicine, Medical University  
Graz, Austria

# No Disclosures






## Endo vs Open, do we have the answer?

**The BEST-CLI With CLTI and the Leg-2)**

**BEST-CLI**  
– August 2014  
– 1830 patients  
Finland, Italy,  
– Patients w/ assigned to Patients w/

Patients  
chemia of

Canada,  
ery were

## Endo vs Open, do we have the answer?



**The BEST-CLI (Best E With CLTI) and BASIL-2 the Leg-2)**

**BASIL- 2 Trial**  
– Between July 22, 2014  
– Randomization 172 (5 endovascular treatme

Patients  
emia of

the trial  
t



|  | Endovascular group (n=172) | Open surgical group (n=172) | Intention-to-treat |
|--|----------------------------|-----------------------------|--------------------|
| Primary endpoint   | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Secondary endpoint   | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Major adverse limb events                                  | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Major amputation   | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Major mortality  | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Minor mortality  | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Quality-adjusted life expectancy                           | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Health-related quality of life                             | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Healthcare costs   | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next revascularization                             | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next major adverse limb event                      | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next major amputation                              | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next major mortality                               | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next minor mortality                               | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next quality-adjusted life expectancy              | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next health-related quality of life                | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next healthcare costs                              | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next time to next revascularization                | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next time to next major adverse limb event         | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next time to next major amputation                 | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next time to next major mortality                  | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next time to next minor mortality                  | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next time to next quality-adjusted life expectancy | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next time to next health-related quality of life   | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |
| Time to next time to next healthcare costs                 | 100 (58.2%)                | 100 (58.2%)                 | NS (P=0.99)        |

## Endo vs Open, do we have the answer?

**Best-CLI**  
Several concerning aspects of the study that must be recognized



1. Trial defined technical failure for endovascular therapy as the inability to cross a stenosis or occlusion or a residual obstruction of >50% in the superficial femoral artery, popliteal artery, and/or all tibial arteries such that there is no in-line flow
  - The failure rate of Cohort 1 was 15.3%, which is a higher incidence than that reported in contemporary data and similar to the results of the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial conducted 17 years ago
2. BEST-CLI trial included patients undergoing infrainguinal revascularization intervention and the BASIL-2 trial included patients who were undergoing infrapopliteal revascularization
3. Reintervention in the endovascular group was the major driver of the composite endpoint
  - 42.5% of first reinterventions occurred within 30 days in the endovascular arm of Cohort 1
4. 73% of endovascular procedures were performed at sites with non high volume endoprocdures
5. Inclusion lasted years (before COVID!!!!) whereas there is a high number of CLTI patients

## Endo vs Open, do we have the answer?

**RealWorld in Contrast/Medicare Data**



- 66,153 patients were included in this study (10,125 autologous grafts; 7867 nonautologous grafts; 48,161 endovascular)
- Compared with BEST-CLI cohort 1, patients in this study were older (mean age, 73.5 ± 5.7 vs 69.9 ± 9.9 years), more likely to be female (38.3% vs 28.5%), and presented with more comorbidities
- Endovascular operators for the study population vs BEST-CLI cohort 1 were less likely to be surgeons (55.9% vs 73.0%) and more likely to be cardiologists (25.5% vs 14.5%)

### Endo vs Open, do we have the answer?

**RealWorld in Contrast/Medicare Data**

- Long-term outcomes:
  - Crude risk of death or MALE in this cohort was higher with surgery
  - 56.6% autologous grafts vs 42.6% BEST-CLI cohort 1 at a median of follow-up 2.7 years
  - 51.6% nonautologous grafts vs 42.8% BEST-CLI cohort 2 at a median follow-up of 1.6 years
  - but similar with the endovascular cohort (58.7% Medicare vs 57.4% cohort 1 at 2.7 years; 47.0% Medicare vs 47.7% cohort 2 at 1.6 years)
  - Of those who received endovascular treatment, the risk of incident major intervention was less than half in this cohort compared with the trial cohort (10.0% Medicare vs 23.5% cohort 1 at 2.7 years; 8.6% Medicare vs 25.6% cohort 2 at 1.6 years)






Serrano et al. Am J Cardiol. 2024;168:149-156. doi:10.1016/j.amjcard.2024.01.007

### Endo vs Open, do we have the answer?

**RealWorld in Contrast/Medicare Data**

- Conclusions: These results suggest that the findings of the BEST-CLI trial may not be applicable to the entirety of the Medicare population of patients with CLTI undergoing revascularization.






Serrano et al. Am J Cardiol. 2024;168:149-156. doi:10.1016/j.amjcard.2024.01.007

### Endo vs Open, do we have the answer?

**An Endovascular- Versus a Surgery-First Revascularization Strategy for Chronic Limb-Threatening Ischemia: A Meta-Analysis of Randomized Controlled Trials**




- A total of 3 RCTs with 2,627 patients (1,312 endovascular-first and 1,315 surgery-first) were included in the meta-analysis
- 1,864 patients (70.9%) were men and 347 (13.2%) were older than 80 years.
- Comparing the endovascular-first and surgery-first approaches, there was no significant difference in the overall (HR 0.92 [0.83 to 1.01], p = 0.09) or amputation-free survival (HR 0.98 [0.92 to 1.03], p = 0.42), reintervention (RR 1.24 [0.74 to 2.07], p = 0.41), major amputation, (RR 1.16 [0.87 to 1.54], p = 0.31), or therapeutic crossover (RR 0.92 [0.37 to 2.26], p = 0.85)
- In conclusion, data from available RCTs suggest that there is no difference in clinical outcomes between endovascular-first and surgery-first revascularization strategies for CLTI
- A planned patient-level meta-analysis may provide further insight

Andrew WB et al. Am J Cardiol. 2024;168:149-156. doi:10.1016/j.amjcard.2024.01.007

### Endo vs Open, do we have the answer?

**An Endovascular- Versus a Surgery-First Revascularization Strategy for Chronic Limb-Threatening Ischemia: A Meta-Analysis of Randomized Controlled Trials**







Andrew WB et al. Am J Cardiol. 2024;168:149-156. doi:10.1016/j.amjcard.2024.01.007

### Controversy Surgical/Endo CLI

**ESC 2024 Recommendations/(CLTI)**

| Recommendations   | Class | Level |
|---|-------|-------|
| In CLTI patients, it is recommended to perform revascularization as soon as possible.   | I     | B     |
| In CLTI, it is recommended to use autologous veins as the preferred conduit for infra-inguinal bypass surgery.  | I     | B     |
| In multilevel vascular disease, it is recommended to eliminate inflow obstructions when treating downstream lesions.  | I     | C     |
| An individual risk assessment (weighing the patient's individual procedural risk of endovascular vs. surgical revascularization) by a multidisciplinary vascular team is recommended. | I     | C     |
| In CLTI patients with good autologous veins and low surgical risk (<5% peri-operative mortality, >50% 2-year survival), infra-inguinal bypass may be considered.                      | IIB   | B     |
| In CLTI patients, endovascular treatment may be considered as first-line therapy, especially in patients with increased surgical risk or inadequate autologous veins.                 | IIB   | B     |






2024 ESC Guidelines for the management of PAD and acute atherosclerosis. Eur Heart J. 2024 Aug 29;45(17):1-19. doi:10.1093/eurheartj/ehae179. Online ahead of print.

### Controversy Surgical/Endo CLI

**2024 How should we proceed?**

- First of all stop fighting who can do it better
- It is not specialty which counts it is the patient who counts
- Patients are different especially CLI patients
- They need to be evaluated by multidisciplinary vascular team approach what kind of treatment should be applied

Thank you for your attention

